Reunion Neuroscience Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Gregory T. Mayes
- Full Time Employees
- 16
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 30 Duncan Street Toronto ON Canada M5V 2C3
- IPO Date
- Oct 7, 2020
- CIK
- 0001865482
- Website
- fieldtriphealth.com
- Similar Companies
- Business
- Reunion Neuroscience Inc. is a clinical-stage biopharmaceutical company focused on developing innovative serotonergic psychedelic therapeutics for underserved mental health disorders, including postpartum depression and adjustment disorder. The company advances RE104, its lead product candidate, a proprietary patented prodrug of 4-OH-DiPT designed to provide a short-duration psychedelic experience with rapid onset, durable antidepressant effects, and a favorable safety profile similar to psilocybin but lasting 3-4 hours; RE245, a discovery-stage non-psychedelic molecule structurally akin to classic psychedelics with selective serotonin 2A receptor potency and no off-target 5HT2B agonism for chronic treatment indications; and the preclinical RE200 series of compounds targeting enhanced receptor selectivity for additional neuropsychiatric applications. RE104 undergoes evaluation in the RECONNECT Phase 2 trial for moderate-to-severe postpartum depression, with last patient dosing completed in May 2025, and the planned REKINDLE Phase 2 trial for adjustment disorder in cancer and other medical illnesses. Founded in 2022 as a successor to Field Trip Health Ltd. and previously taken private in August 2023 via a US$13.1 million transaction with MPM BioImpact, Reunion Neuroscience is headquartered in Morristown, New Jersey, and operates primarily in North America. In May 2024, the company closed a $103 million Series A financing round co-led by MPM BioImpact and Novo Holdings, with participation from Arkin Bio Capital, Mitsui & Co. Global Investment, Plaisance Capital, FemHealth Ventures, and Palo Santo, to fund clinical pipeline advancement. Recent milestones include publication of RE104 Phase 1 data in The Journal of Clinical Psychopharmacology in July 2025.
Reunion Neuroscience to Present Full Data from RECONNECT Phase 2 Clinical Trial at Upcoming ASCP and APA Annual Meetings
U.S. FDA Grants Reunion Neuroscience's Luvesilocin (RE104) Breakthrough Therapy Designation Status
Reunion Neuroscience to Participate in Upcoming Investor Conferences
Reunion Neuroscience Announces Program Updates and Highlights Anticipated 2026 Milestones
Reunion Neuroscience Announces First Patient Dosed in REKINDLE Phase 2 Clinical Trial of RE104 for the Treatment of Adjustment Disorder (AjD) in Cancer and Other Medical Illnesses
Reunion Neuroscience Announces Final Closing of its Series A Financing and Plans to Advance RE104 into Clinical Development for the Treatment of Generalized Anxiety Disorder (GAD)
Reunion Neuroscience Announces Positive Topline Results from RECONNECT Phase 2 Clinical Trial of RE104 for the Treatment of Postpartum Depression (PPD)
Reunion Neuroscience Announces Publication of RE104 Phase 1 Data in The Journal of Clinical Psychopharmacology
Reunion Neuroscience Announces Last Patient Dosed in RECONNECT Phase 2 Clinical Trial of RE104 for the Treatment of Postpartum Depression (PPD)
Reunion Neuroscience Presents REKINDLE, a Phase 2 Clinical Trial Evaluating RE104 for the Treatment of Adjustment Disorder (AjD) in Cancer and Other Medical Illnesses at the Anxiety & Depression Association of America (ADAA) 2025 Conference
Reunion Neuroscience Announces Participation in Premiere Maternal Mental Health Event
Reunion Neuroscience Announces Program Updates and Highlights Anticipated 2025 Milestones
Reunion Neuroscience Presented RE104 Phase 1 Data at the 2024 American College of Neuropsychopharmacology (ACNP) 63rd Annual Meeting
Reunion Neuroscience Partners with Seleni Institute on Effective Diagnosis and Treatment of Maternal Mental Health Disorders
Reunion Neuroscience Appoints Mark Pollack, M.D., as Chief Medical Officer
Reunion Neuroscience Joins the Is Mom OK? Initiative Recognizing Maternal Suicide Prevention Month
Reunion Neuroscience Inc. Announces Upcoming Presentations at the Anxiety and Depression Association of America (ADAA) 2024 Conference
Reunion Neuroscience Inc. to Participate in October Investor Conferences
Reunion Neuroscience Inc. Announces FDA Clearance of IND Application to Initiate a Phase 2 Study of RE104 for the Treatment of Postpartum Depression
Reunion Neuroscience Inc. and MPM BioImpact Announce Completion of Plan of Arrangement